Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

Bausch Health (BHC) has agreed to acquire DURECT Corp (DRRX) for an upfront payment of $63 million ($1.75/share) and up to $350 million in potential milestone payments. The acquisition primarily targets larsucosterol, a novel therapeutic molecule for alcoholic hepatitis (AH) that demonstrated promising Phase 2 results and is now slated for a registrational Phase 3 trial, addressing a condition with no currently FDA- or EMA-approved treatments. This move expands Bausch Health's hepatology pipeline and complements its existing clinical programs, as the company continues to manage its substantial debt. DURECT's stock surged over 238% on the news.

Analysis

Bausch Health (BHC) is strategically expanding its hepatology pipeline through the acquisition of DURECT Corp (DRRX) in an all-cash deal valued at $63 million upfront, with up to $350 million in potential sales-based milestone payments. The central asset is larsucosterol, a late-stage therapeutic for alcoholic hepatitis (AH) that has shown promising Phase 2 results. This acquisition addresses a significant unmet medical need, as there are currently no FDA- or EMA-approved treatments for AH. The planned registrational Phase 3 trial, designed with FDA feedback under a Breakthrough Therapy Designation, will target a primary endpoint of 90-day survival, representing a high-value clinical outcome. This move complements Bausch Health's existing RED-C clinical program and demonstrates a focused effort to build a specialized portfolio, despite the company's overarching challenge of managing approximately $21 billion in debt. The market reaction underscores the value unlocked for DURECT, whose stock surged over 238%, while Bausch Health's stock saw a marginal decline of 0.36%, reflecting the modest upfront cost and the assumption of inherent clinical development risk against the long-term potential of the asset.

Key Decisions for Investors

• For Bausch Health investors, this acquisition represents a long-term strategic bet on its hepatology pipeline; focus should be on the company's ability to manage its significant debt load while funding the pivotal Phase 3 trial for larsucosterol.
• Shareholders of DURECT have realized a significant upfront gain, and should now evaluate the probability of larsucosterol achieving commercial success to assess the potential value of the $350 million in contingent milestone payments.
• The deal signals strong M&A interest in de-risked, late-stage clinical assets targeting indications with no approved therapies, suggesting investors should monitor small-cap biotech firms with assets that have received Breakthrough Therapy Designation as potential acquisition targets.